Supply Shortages Of Cerezyme And Fabrazyme - Priority Access Forpatients Most In Need Of Treatment Recommended

The European Medicines Agency’s (EMEA) Committee for Medicinal Products for Human Use (CHMP) has recommended that patients who are in greatest need of treatment are given priority access to Cerezyme (imiglucerase) and Fabrazyme (agalsidase beta) during the expected supply shortage of these two medicines over the next few months. Cerezyme and Fabrazyme are both used to treat rare, inherited enzyme-deficiency disorders.

More: continued here

Filed under: Pharma Industry on June 30th, 2009